

# OnCore Protocol Naming Conventions

22 March 23

Protocol Name is limited to 25 characters

There can be no blank spaces in a name

The only allowable non-alphanumeric character is a dash (-)

CCCTO AAs and Research Managers, Peds Oncology Research Managers and OnCore Support are currently the only users who can enter in a new protocol and therefore enter protocol names. They should follow these guidelines:

## Cancer Center Naming:

- **Pharmacy/Industry Trials:** Drug Company Name-Sponsor Protocol Name, e.g. MERCK-055
  - Company names may be shortened due to space limitations, for example AstraZeneca as AZ.
  - Where multiple sponsors, use the funding sponsor in the name.
- **Cooperative Group:** Group Name-Sponsor Protocol Name, e.g. ALLIANCE-A011203.
- **Foundation Trials** – Pharmacy/Industry trials that are opened in collaboration with or requiring membership in a cooperative group/consortium: Group Name-Sponsor Protocol Name, e.g. COG-AAML1321. Please review OnCore Communication Memo #25 – Foundation Trials Sponsor Designation.
- **Consortium Trials** – Pharmacy/Industry trials that are open in collaboration with or requiring membership in a consortium group: Drug Company Name-Sponsor Protocol Name-Consortium Name or initials, e.g. BERG-15-022.
- **Investigator-Initiated Trials:** IIT-PI Last Name-Commonly Used Protocol Name, e.g. IIT-ATALLAH-LAST-TKI.
- **External Investigator-Initiated Trials** – IIT (institutional) studies from other colleges/hospitals opened at MCW/Froedtert/CHW, where the external site is the coordinating center: Center name or initials-Protocol or Commonly Used Name, e.g. UMICH-ANTI-PD-1.
- **Expanded Access Trials** – Facilitates access to drugs or devices where the subject(s) may not be eligible to go on a trial but could benefit from the therapeutic option: EAP-Drug Company Name-Sponsor Protocol Name, e.g. EAP-JANSSEN-SAR-3002.
- **Treatment Use Only Trials (Compassionate Use Trials)** – Subject(s) who were enrolled on a study are given IRB permission to continue to use the study drug(s) even though they have gone off-study: TX-Drug Company Name-Sponsor Protocol Name, e.g. TX-GLOBE-G14000-14.
- **Emergency Investigative Drug or Device Use Trials** – Subject(s) are given IRB permission to emergently use an experimental therapeutic option, not on-study, for a particular disease/diagnosis/symptom: EIND-Drug Company Name-Drug Name, e.g. EIND-ANSUN-DAS181.

**Non-Cancer Naming:**

- Non-cancer studies will follow the same guidelines as above, with the exception that they will add their Department/Division as a prefix to the Protocol Name. Prefixes are as follows (below). This list will be updated as new Departments/Divisions start to use OnCore.

• ABA - Abandoned– include after study moves to this status	• NEURO - Department of Neurology
• BIOPHY - Biophysics	• NSUR - Neurosurgery
• BSM - MCW Tissue Bank	• OBG - OB/GYN Non-oncology
• CRI - Children’s Research Institute Biobank	• OPH - Ophthalmology
• CVC - Cardiovascular	• OTO - Otolaryngology
• DERM - Dermatology	• P - Pediatric non-oncology studies use the same division names as adult but add a P- as a prefix before the prefix
• ENDO - Endocrinology	• PATH - Pathology
• GI - Gastroenterology	• PLS – Plastic Surgery
• GIM - General Internal Medicine	• PULM - Pulmonary
• HEMONC - Non-oncology HemOnc	• RHEU - Rheumatology
• HHI - Herma Heart Institute	• SURG - Department of Surgery
• INF - Infectious Disease	• VIR - Vascular Interventional Radiology
• NEPH - Nephrology	